INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death in end stage renal disease (ESRD) (1) . Most chronic hemodialysis (HD) patients have serious structural and functional cardiovascular abnormalities before the appearance of CVD symptoms (2) . Early diagnosis of and intervention for CVD may improve the prognosis, morbidity and mortality (1) . However, most of the cardiovascular risk scoring systems used for the general population may not be applied for HD patients equally (3) . More accurate and reliable markers for early detection of cardiac injury are required for HD patients before the onset of cardiovascular symptoms (4, 5) .
Cardiac biomarkers that provide information about left ventricular mass and function are used in the diagnosis of CVD in the general population (6) . Left ventricular hypertrophy (LVH) and left ventricular dysfunction are among the predictors of cardiovascular mortality in ESRD patients (7) . Therefore, the use of cardiac biomarkers in CVD risk assessment of asymptomatic HD patients has attracted considerable interest.
In our study, we aimed to investigate the association of troponin-T (Tn-T), heart type fatty acid binding protein (H-FABP) and N-terminal pro-brain natriuretic peptid (NTproBNP) levels with clinical, echocardiographic and laboratory parameters of asymptomatic HD patients. Furthermore, we tried to determine cut-off values that can be used for HD patients.
MATERIALS and METHODS
The study protocol was approved by the local ethics committee. A total of 60 HD patients and 62 healthy subjects were enrolled. HD was performed three times a week and four hours per session by using synthetic dialysers (polysulphone membranes for all) with a surface area of 1.5 m 2 . All the patients whose target dry weight (normal blood pressure without symptomatic orthostatic hypotension and clinical fluid overload) had already been achieved were included in the study.
Interdialytic weight gain did not exceed 3% in the preceding month and no extra session for ultrafiltration and dialysis was required during this period.
Demographic features (age, sex, body mass index, blood pressure, smoking) for both groups were evaluated. Primary kidney diseases, dialysis duration, interdialytic weight gain, medications, residual renal function, predialysis systolic and diastolic blood pressure values were all recorded.
Patients with acute coronary syndrome, decompensated heart failure, and patients who had ischemic changes on the electrocardiogram and arrhythmia in the last 6 months were excluded. Patients with a history of recent cardiac catheterization, chronic obstructive lung disease, pulmonary thromboembolism, malignant disease, and an acute or chronic inflammatory process were also excluded. Patients who took cardiotoxic drugs, those who were treated for myocarditis in the last 6 months, and patients whose interdialytic weight gain was >3% were all excluded from the study. Patients who had arrhythmia affecting HD hemodynamics during HD sessions, and patients who had severe fluctuations in blood pressure or hypoxemia during HD sessions were also excluded.
Laboratory Studies
Biochemical Tests: All blood samples were collected at the beginning of the HD session in order to prevent possible influences of the dialysis process itself on the concentrations of the different parameters. Serum levels of urea, serum creatinine, albumin, uric acid, fasting blood glucose, and serum lipid parameters (total cholesterol, high density lipoprotein [HDL] , and low density lipoprotein [LDL], triglyceride) were measured by the photometric method. Sodium, potassium, chloride ions were measured by the ion selective electrode (ISE) method, whereas C-reactive protein (CRP) was measured by the immunoturbidimetric method using an autoanalyzer (Cobas 501 Roche Mannheim, Germany).
Hemoglobin levels were measured with an autoanalyzer (Sysmex XT 2000i, Roche Mannheim, Germany). Serum parathyroid hormone (PTH) and serum ferritin levels were measured using an electrochemiluminescence method (Modular E170, Roche Mannheim, Germany). Tn-T was measured by an electrochemiluminescence method that depended on the sandwich principle, using an autoanalyzer (Modular Analytics E170, Roche, Mannheim Germany). H-FABP was analysed with a Sandwich ELISA method (Medcompare diagnostics, Triturus EIA Analyzer, Grifols, USA). NT-proBNP was measured with an electrochemiluminescence immunoassay method using the Cobas E immunoassay analyzer (Roche diagnostics, GmbH, Mannheim, Germany).
Electrocardiography: 12-lead electrocardiography was performed for all patients using the EDAN SE-12 device.
Echocardiography:
Transthoracic echocardiography was performed for all patients by the same cardiologist (T.Ö.) who was unaware of the patients' clinical information. Echocardiography was performed with 2D and M-mode imaging in the parasternal and apical windows while the patients were in the left lateral decubitus position (PHILIPS HD11XE, Netherland).
Associations between echocardiographic parameters and biochemical markers were evaluated.
Statistical Analysis
The MedCalc statistical program was used for data analysis. Power analysis was performed with 0.05 Type I and 0.20 Type II error (0.80 power), and it was revealed that at least 40 patients were required for the study. Mean, median, standard deviation and frequency values were obtained. The Shapiro-Wilk test was used for continuous measurements (HD duration etc.) to test the convenience of a normal distribution for permanent data. Differences between groups were evaluated with the t-test or Mann-Whitney U test. Relationship between continuous measurements were analyzed by the Pearson correlation test or the Spearman rank correlation test. The association between categorical variables was evaluated with the chi square test. ROC curve analysis was applied in order to determine the power of continuous variables to discriminate patients and healthy subjects. Statistical significance was defined by a p value less than 0.05.
RESULTS

Demographic Findings
A total of 60 HD patients and 62 healthy subjects were enrolled. Both groups were similar for age, sex, smoking and alcohol use (p>0.05). Demographic features of the patient group and distribution of the patients by primary renal disease and drugs used are shown in Table I , whereas laboratory results and echocardiographic findings of HD patients are summarized in Table II. Cardiovascular risk factors (smoking, dyslipidemia, hypertension, diabetes, obesity) were evaluated in HD patients. All of the patients (n=60) had at least one CVD risk factor in addition to chronic kidney disease (CKD), whereas 80% (n=48) had 2, 51.3% (n=31) had 3, 23.3% (n=14) had 4, and 13.3% (n=8) had 5 CVD risk factors.
Tn-T, H-FABp and NT-proBNp Levels
Serum levels of Tn-T, H-FABP, and NT-proBNP levels were higher in the patients than in the control group (Table III) . 
Association Between Tn-T, H-FABp, NT-proBNp and Demographic and Biochemical parameters
There was no relationship between cardiac biomarkers and age, sex, HD duration, interdialytic weight gain, hemoglobin, and PTH levels. An inverse correlation existed between plasma albumin and NT-proBNP levels (r=-0.29, p<0.05). Besides, there was a negative correlation between CRP and NT-proBNP levels (r=-41, p<0.01).
Association Between Left Ventricular Hypertrophy and Tn-T, H-FABp, NT-proBNp
Tn-T and H-FABP levels did not reach statistical significance among the patients with and without LVH (p>0.05) (Table  IV) . However, LVH was more likely to be present when NTproBNP was higher then 12914 pg/ml. Discriminating power of NT-proBNP for LVH (sensitivity) was 44% whereas it was 91.2% for a normal ventricle (specificity) (Receiver operating characteristic [ROC] curve analysis). Area under the curve was 0.663 (0.528 -0.781) (p=0.022) (Figure 1 ).
Association Between pericardial Fluid and Tn-T, NTproBNp, H-FABp
Only 3 patients had pericardial effusion. There was no significant difference for the 3 biomarkers between the patients who had and who did not have pericardial fluid (p>0.05).
Association Between pulmonary Artery pressure and Tn-T, H-FABp, NT-proBNp
H-FABP was significantly higher in patients with higher pulmonary artery pressure (p=0.025) ( Table V) . ml and patients with tricuspid valve regurgitation: 1.51±1.69 ng/ ml) (p=0.025). Tricuspid valve regurgitation was more common when the H-FABP level was >1 pg/dl. However, sensitivity was 95% whereas specificity was 33% (ROC curve analysis). Area under the curve was 0.676 (0.543 -0.791) (p=0.012) (Figure 2 ).
Table IV. Association between LVH and Troponin-T, H-FABP, NT-proBNP levels.
Biomarkers LVH***(-), n=35 LVH (+), n=25 p
Other Results
Tn-T, H-FABP, NT-proBNP were not associated with echocardiographic parameters such as diastolic interventricular septum thickness, diastolic wall thickness, ejection fraction, fractional shortening, aortic diameter, aortic velocity, pulmonary velocity, pulmonary artery pressure and left atrial enlargement (p>0.05).
NT-proBNP was significantly higher in hypertensive patients (p=0.038), whereas there was no significant change in Tn-T and H-FABP levels (p=0.552). There was no difference in Tn-T, H-FABP and NT-proBNP levels between patients with and without diabetes mellitus (p>0.05).
Cardiac biomarkers used in this trial had no correlation with each other. No statistically significant relationship existed between the number of cardiovascular risk factors, type of antihypertensive drugs, use of erythropoietin, and Tn-T, H-FABP, NT-proBNP levels.
DISCUSSION
Cardiac biomarkers have attracted interest in screening CVD and predicting cardiovascular outcomes. These biomarkers may allow early intervention for CVD to improve outcomes. Asymptomatic chronic HD patients should be the target population for cardiovascular risk modification and intervention.
However, decreased renal clearance needs to be considered as the plasma levels of these biomarkers may be affected. Therefore, the reference values that are used for general population cannot be used for ESRD patients (8) . Different cutoff values need to be determined for them. Serum Tn-T, H-FABP and NT-proBNP levels (molecular weight of H-FABP: 15 kDa, Troponin T: 35 kDa, NT-Pro BNP: 8,400 Da) may be influenced by the dialysis process (9) (10) (11) . For this reason, all blood samples were collected at the beginning of the HD session in our study.
Tn-T is one of the most common myocardial ischemia markers used today. In asymptomatic HD patients, elevated Tn-T is related to both cardiac and all cause mortality (12, 13) . As elevated Tn-T seems to be associated with a poor prognosis, Tn-T monitoring has become more popular in cardiovascular risk assessment and therefore in treatment planning (14) . Tn-T can detect subclinical myocardial cell injury due to recurrent cardiac stress induced by HD sessions and relative ischemic stress related to cardiac remodelling due to heart failure and LVH (12) . Although a relationship between elevated Tn-T and LVH has been reported (15) , the association between Tn-T and mortality was found to be independent of the presence LVH (16) . In our study, Tn-T levels were higher in asymptomatic HD patients than in control subjects. However, this finding did not correlate significantly with any clinical or laboratory parameters. Clinical significance of the elevation of Tn-T remains unclear.
H-FABP is another cardiac biomarker that can be used in myocardial injury detection (17) . H-FABP is released from myocardial cells following an ischemic period. It is a biomarker for early diagnosis of acute myocardial infarction. However, as H-FABP is excreted by the kidneys, its diagnostic value is limited in CKD. High levels of H-FABP may present in HD patients even in the absence of myocardial injury (18) . H-FABP can also predict outcome in patients with acute pulmonary embolism (19) . Besides, recent studies have documented the association between elevated H-FABP levels and poor cardiac prognosis in chronic thromboembolic pulmonary hypertension (17) . In our study H-FABP levels were significantly higher in the patients than the control subjects. In addition, H-FABP was significantly higher in the presence of higher pulmonary artery pressure and tricuspid regurgitation. We found that tricuspid valve regurgitation was more common when H-FABP level was >1 pg/dl (sensitivity: 95%, specificity: %33) ( Figure  2 ). Pulmonary hypertension is an independent risk factor for mortality in HD patients (20) . An elevated H-FABP level may therefore indicate a poor prognosis in HD patients.
The natriuretic peptide BNP and its inactive form NT-proBNP are secreted from cardiac myocytes as markers of myocardial wall stress (21) . NT-proBNP has become increasingly important in the diagnosis of left ventricular dsyfunction and is excreted by the kidneys. The plasma level of NT-proBNP is higher in ESRD patients and only a small fraction is removed by HD (21) . In CKD, an increase in NT-proBNP without left ventricular 
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Bardak S et al: Cardiac Biomarkers dysfunction may be due to either decreased renal excretion (7, 22) or chronic volume excess (23) . Inflammation, nutritional status, comorbidities, and dialyser membranes are among the factors affecting NT-proBNP (9, 24) . For this reason, some trials have declared that NT-proBNP is not a useful biomarker for CVD in HD patients (7) . In our study, we found higher NTproBNP levels in HD patients, but there was no difference for NT-proBNP levels between the patients with and without LVH. This suggests that the increase in NT-proBNP level is not caused by myocardial pathology and elimination kinetics or variable volume status may be the underlying reasons instead. Although the absence of a relationship between left ventricular mass and NT-proBNP levels was parallel to some other trials (7, 21) , studies with opposing conclusions are also present in the literature (25, 26) .
The cutoff values of NT-proBNP for HD patients may help discriminate between left ventricular dysfunction and chronic volume excess (27) . The optimal cutoff values of NTproBNP are not well defined for HD patients (7, 28) . David S and al. documented that an NT-proBNP level ≥7200 ng/L could discriminate patients with left ventricular dysfunction with 80% sensitivity and 90% specificity. In the same study, a negative correlation was found between the NT-proBNP level and ejection fraction (27) . In another study, the NT-proBNP level with a digit number of 5 or greater was found to be associated with cardiovascular diseases in ESRD patients. An NT-proBNP level of 10000 pg/mL was determined as the best cutoff level for left ventricular systolic dysfunction whereas a level of 6000 pg/mL was the best cutoff level for the diagnosis of coronary artery disease in ESRD patients (29) . In our study, there was a statistically significant relationship between an NT-proBNP level >12914 pg/ml and LVH. However, no correlation was found between the NT-proBNP level and ejection fraction.
Malnutrition and inflammation may affect the NT-proBNP level (29) . Therefore, interpretation of the NT-proBNP level is even more challenging in the coexistence of overhydration, malnutrition and inflammation in HD patients (30) . In our study, there was an inverse correlation between plasma albumin, CRP and NT-proBNP levels. This association may have contributed to the absence of correlation between the ejection fraction and NT-proBNP levels.
In our study, NT-proBNP levels were higher in hypertensive patients than in normotensives. This can be expected as the hypertension in HD patients is mostly due to a positive water and sodium balance.
Despite the studies reporting higher NT-proBNP levels in HD patients with pulmonary hypertension (31), a similar association was not found in our study. This might be related to the small size of our study population.
The combined index of cardiovascular risk factors could supply additional information about cardiovascular mortality in HD patients (32) . However, in our study there was no correlation between the cardiac biomarkers. Biomarkers that are popular for general population need to be defined better in HD patients.
Study Limitations
One of the limitations of this study is the small number of groups. The second is that the cardiac biomarkers were measured only once and no serial measurement had been performed.
CONCLUSIONS
Tn-T, H-FABP and NT-proBNP levels are higher in asymptomatic HD patients. Nonetheless there are not strong correlations between the biomarkers and cardiac abnormalities and cut-off values for cardiac abnormalities should be determined in such these patients.
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